GENOVA Q1 FY2027 Earnings Deep Dive Report

GENOVA Inc.'s financial results for the first quarter of the fiscal year ending March 2027 show consolidated net sales reaching 3.05 billion yen (up 164.7% year-on-year) , marking a record-high revenue for a first quarter. This significant growth was driven by the steady performance of core existing businesses, bolstered by the consolidation of the dental distribution business (ASANO Co., Ltd. and Akasaka Dental Materials Co., Ltd.).

Meanwhile, the company reported a temporary operating loss of 220 million yen (compared to a 170 million yen loss in the same period last year) . This was primarily due to aggressive investment in human capital to ensure sustainable future growth, increased recruitment and compensation improvements, and higher cost of sales (manufacturing expenses) associated with M&A activities. However, thanks to a 490 million yen extraordinary profit resulting from the waiver of stock acquisition rights, the company secured a net income attributable to owners of the parent of 240 million yen .

This report provides a comprehensive analysis of the company's performance structure, the breakdown of upfront investments, segment-specific trends, and the group's future synergy and growth narrative, centered on 10 key topics identified from the earnings presentation materials.

---

1. Performance Summary and Rapid Top-Line Expansion

The most significant topic for Q1 FY2027 is the rapid scaling of net sales. Revenue increased by a net 1.20 billion yen (+64.7%) , rising from 1.85 billion yen in the same period last year to 3.05 billion yen.

The slide below illustrates the quarterly business revenue trends over the past three years.

As the graph above indicates, GENOVA’s revenue structure has evolved from a two-pillar model—consisting of the "Medical Platform Business" and "Smart Clinic Business"—to a three-pillar model with the addition of the "Dental Distribution Business" acquired through M&A.

The reason this slide is critical is that it clearly quantifies the results of an M&A strategy that achieves non-linear growth, in addition to GENOVA's standalone growth. Looking at standalone sales alone, the company achieved 116% year-on-year growth , demonstrating that the core business maintains a strong growth trend while the dental distribution business (820 million yen in quarterly sales) has been successfully integrated as a new revenue pillar.

---

2. Changes in Profit Structure and Breakdown of Upfront Investments

While sales grew significantly, consolidated operating profit resulted in a 220 million yen loss. The background to this shift into the red—and the expansion of that loss—lies in the company's "concentrated investment in human capital."

To strengthen long-term competitiveness, the company is actively enhancing recruitment, improving compensation for existing employees (base pay increases), and increasing the number of new graduate hires. Looking at the breakdown of total expenses, manufacturing costs (cost of sales) were 1.52 billion yen, and personnel expenses were 940 million yen; the latter increased by 180 million yen year-on-year .

The slide below shows the specific breakdown of human capital investment at the GENOVA standalone level.

The reason this slide is important is that it proves the increase in expenses—the primary cause of the operating loss—is not merely cost bloat, but rather "upfront investment in growth talent" with a clear strategic intent.

The specific breakdown is as follows:

• Recruitment expenses : Increased from 53 million yen to 78 million yen (+25 million yen YoY) , strengthening investment to acquire top-tier talent.
• Salaries and compensation : Increased from 450 million yen to 520 million yen (+70 million yen YoY) , reflecting base pay increases for all employees and an increase in new graduate hires.
• Bonuses and bonus provisions : Expanded from 9 million yen to 38 million yen (+29 million yen YoY) , boosting motivation through increased performance-based rewards.
• System implementation costs : 7 million yen newly recorded for AI Transformation (AX) and the strengthening of HR/recruitment infrastructure.

In total, an additional 131 million yen in human capital investment at the standalone level was the direct factor pushing down operating profit. This can be interpreted as a proactive upfront investment directly linked to building the human foundation that will support future business expansion.

---

3. Segment Performance and KPI Trends

The performance and key KPI trends for each business segment are as follows:

① Medical Platform Business (Medical DOC)

• Net Sales : 1.14 billion yen ( 107.3% YoY)
• Key KPI (PVs) : Rapid recovery to a monthly average of 21.84 million PVs
• Number of Services Acquired : 105% YoY (+49 contracts)
• Analysis : While PVs had plateaued around the third quarter of the previous fiscal year, the strengthening of the article production system implemented last term has borne fruit, with PVs surging past the 21 million mark. This expansion in PVs functions as a patient-attraction engine, driving orders (acquisitions) for introduction articles and videos for medical institutions.

② Smart Clinic Business (NOMOCA Series, etc.)

• Net Sales : 970 million yen ( 144.7% YoY; 129.8% on a standalone basis)
• Number of Hardware Services Acquired : 147% YoY (134 units)
• Cumulative Hardware Installations : 3,045 units
• Analysis : Orders and deliveries of hardware, centered on automated payment machines and reception kiosks (NOMOCA-Stand, etc.), were exceptionally strong. Meanwhile, software services such as AI chat and AI calls remained flat at 220 contracts (101% YoY) due to the focus on hardware delivery, but the Smart Clinic business as a whole showed extremely high growth of 44.7% YoY.

③ Dental Distribution Business (ASANO / Akasaka Dental Materials)

• Net Sales : 820 million yen
• Analysis : Following the acquisition of the long-established Hokuriku-based ASANO Co., Ltd., the company acquired a stake in Saitama-based Akasaka Dental Materials Co., Ltd. in April 2026, making it a subsidiary. By securing the dental material distribution and supply chain domain, the company has acquired a stable, high-recurring (stock-type) revenue base.

---

4. Group Synergies and Future Growth Story

Essential to understanding GENOVA's sustainable growth are its high repeat rates and cross-selling synergies with M&A targets.

Looking at the ratio of new to existing customer sales in standalone performance, existing customers account for 77.2% . This is evidence of the high cross-selling and resale capabilities leveraged through the touchpoints with medical institutions that the company has cultivated over its 21-year history.

Furthermore, the cross-selling initiative utilizing the group-wide customer base expanded through M&A is shown in the slide below.

The strategic value shown in this slide lies in the "low overlap" and "potential for mutual cross-selling" within the customer bases of the companies brought into the group.

Currently, the total number of unique group customers has reached approximately 21,700 (GENOVA: 18,000; ASANO: 3,500; Akasaka Dental Materials: 1,000), but customer overlap is only about 800 . This means that for the remaining 20,000+ customers , the following mutual approaches are possible:

1. Proposing GENOVA’s DX products (Smart Clinic) and web patient-attraction services (Medical Platform) to dental clinics held by the dental distribution business (ASANO/Akasaka).
2. Providing dental material supplies and supply chain efficiency solutions to GENOVA’s existing customers.

With recurring revenue added to the flow-based revenue model, and further progress in mutual cross-selling, the structure is set to simultaneously improve customer unit prices and profit margins.

---

5. Shareholder Returns and Future Outlook

Even while in an upfront investment phase for business expansion and organizational development, the company has clearly stated its commitment to shareholder returns.

• Annual Ordinary Dividend per Share (Forecast) : 30 yen
• Dividend Payout Ratio : 43.6%
• Total Dividend Amount : Approx. 510 million yen

The company plans to maintain a stable annual dividend of 30 yen while aiming to maximize corporate value through growth investments.

Summary

Although the Q1 FY2027 earnings show a superficial decline in profit due to an operating loss caused by human capital investment , the reality is a powerful top-line growth of 164.7% year-on-year , representing a structural reform and investment period to enhance future competitiveness.

With the recovery of "Medical DOC" PVs improving patient-attraction power, the acceleration of hardware installations in the Smart Clinic business, and the consolidation of the dental distribution business with its massive 21,700-customer base for cross-selling, the pieces for the next leap in growth are falling into place.